Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Dosing and Administration

SHINGRIX should be refrigerated. DO NOT FREEZE:

Store both the antigen and adjuvant between
2º and 8ºC (36º and 46ºF) before reconstitution (discard if frozen).1

SHINGRIX is supplied as an adjuvant and antigen for reconstitution: The antigen is to be reconstituted only with the accompanying adjuvant suspension. After reconstitution, SHINGRIX should be administered immediately or stored refrigerated between 2° and 8°C (36° and 46°F) and used within 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen.1
SHINGRIX is a recombinant vaccine for intramuscular injection only.1

SHINGRIX is administered as a 2-dose series:

The second dose should be administered anytime between 2 and 6 months after the first dose to complete the 2-dose series as directed.1

The CDC has issued guidance on the SHINGRIX dosing schedule2,3,*

  • Following the first dose of SHINGRIX, the second dose should be given 2-6 months later
  • If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. You should not restart the vaccine series
  • However:
    • The efficacy of alternative dosing regimens has not been evaluated
    • Data regarding the safety of alternative regimens are limited
    • Individuals might remain at risk for herpes zoster during a longer than recommended interval between doses 1 and 2

Prescribing SHINGRIX

Reconstitution video

View reconstitution instructions for SHINGRIX.

*In a phase 3 clinical study designed to help establish the dosing interval for SHINGRIX, all primary endpoints were met for dosing at a 0- and 6-month interval when compared to dosing at a 0- and 2-month interval. However, a co-primary endpoint (noninferiority) of the immune response was missed for dosing at a 0- and 12-month interval. (The upper limit of the 97.5% confidence interval was 1.53, above the predefined limit of <1.5.)4 GSK has not studied the safety or immune response of 3 doses of SHINGRIX in the indicated population (patients ≥50 years of age).1

CDC=Centers for Disease Control and Prevention.


  1. Prescribing Information for SHINGRIX.
  2. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108.
  3. Centers for Disease Control and Prevention. Frequently Asked Questions About Shingrix. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html. Updated August 22, 2018. Accessed September 11, 2018.
  4. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148-154.

All trademarks are the property of their respective owners.